Enterprise Value

-68.68M

Cash

237M

Avg Qtr Burn

-20.86M

Short % of Float

5.10%

Insider Ownership

0.96%

Institutional Own.

92.99%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Update

Camonsertib (RP-3500) Details
Cancer, Solid tumor/s

Phase 1/2

Data readout

Phase 1

Data readout

Phase 1

Data readout

Phase 1

Data readout

Phase 1

Data readout

RP-6306 +/- Camonsertib Details
Solid tumor/s, Cancer, Ovarian cancer, Endometrial cancer

Phase 1

Data readout

Phase 1

Initiation